The strength of North China Pharmaceutical Group Ainuo Co., Ltd.

Employees with college education or above account for 68% of the total employees, and technical developers account for 32% of the total employees. The company's pilot plant, strain laboratory, synthesis laboratory and preparation laboratory have good research and development capabilities, advanced fermentation, extraction, purification and synthesis test equipment, as well as high-tech shaking table, HPLC and other analytical and experimental instruments. With the support of excellent personnel conditions and equipment conditions, the technical research and development work of Ainuo Company has been carried out in a vivid way. At present, our company has a number of technical reserves and a number of project cooperation plans, with good development prospects. In addition, as the company's current flagship product, avermectin has outstanding technical reserves and the best strains in China. With the strong support of scientific research and development, the company's production technology level and production capacity have been greatly improved, and the manufacturing costs of avermectin and ivermectin have been the lowest in China. Moreover, the quality of the company's products has also been improved, and all products have reached an excellent level. Due to the advantages of low cost and high quality, all kinds of products produced by our company are very competitive in domestic and international markets.

Since its production, Ainuo Company has carried out in-depth and meticulous marketing work, and its products are sold all over the world. Customers in nearly 20 countries and regions, such as South America, Asia, Europe, North America and Australia, regard Aino as their raw material suppliers. Syngenta is a global supplier of fixed-point procurement and underwriting products, and its products are well received by customers because of their stable quality and reasonable price positioning. In view of many factors such as product cost, variety and quality, the sales revenue of Ainuo Company has increased year by year. The main products have occupied a dominant position in the domestic market, and the export ratio has reached nearly 80% of the company's total turnover. The company's preparation products are widely accepted by the market because they meet the green environmental protection requirements of national sustainable development, and the sales revenue is increasing year by year. In 2008, the sales revenue was more than 200 million yuan. In addition, our products passed the on-site inspection of FDA in June 2004 +065438+ 10, and obtained the European COS certificate in June 2005. With the realization of these two tasks, the share and competitiveness of our products in the international market will be further expanded and strengthened. At present, the company's main products are in short supply in the market.

After several years of development, especially after joining WTO, Ainuo Company has formed its own unique advantages in equipment, production cost, technology, quality and management. On the one hand, due to the strict quarantine system for export products, people's medication habits will be in line with international standards. On the other hand, due to the national protection policy for green pesticides, it will promote the development of related industries and provide AV and IV products for our company.

Therefore, Ainuo Company is willing to make full use of its own advantages, seize the opportunity, work hand in hand with people of insight at home and abroad, and make its own contribution to the development of bio-agriculture and veterinary drug industry in China.